At 12p this looks a great BUY.Remember after the deal with Suvair this shot to around 30p ! Next news I am sure will be the announcement of some major deals.Fill up at this level.

Thanks Global Nomad.
The good thing about this share is that it is an 'ethical buy'. People are presently suffering and dying due to conditions such as MRSA. This product could prevent this from happening. It can help prevent it without the use of invasive drugs, that no longer work anyway.
Lets clean our Hospitals up and start saving lives !

Quite a lot of buys going through today, no sells. I wonder if someone knows something about the results that are due ?

Think the buys must mean that they are close to announcing some strategic changes plus some good orders that they are supposed to have won with a major housebuilder.

Sharesure
this as happened on several occasions over the last month or two
and all to no avail,lets hope this time its for real,

Akel44 : Agreed. Some companies just don't seem to have a full set of dynamic directors. Concerned that this is one of them at the moment, but hopeful that will change by the time of their AGM which is usually in August/September. I cannot believe that they are all doing all they can to make progress. The CEO seems to be, but as for the rest, in partic. the current chairman, I am trying to keep an open mind but expect to be forming a negative view if there is no sudden burst in strategic initiatives on their best way forward.

I just find it difficult to understand why a company should move to larger premisis, look like there getting in the orders if they are not back on the up ?
The share price, which is about the lowest it's been, seems to be as much as anything else a reflection of the Nightingale product potential. When there is some faith that it will succeed the SP jumps otherwise it slumps. It is not a true reflection of the core business itself.
My faith in this company comes from its core, established business products. The sp was valued far higher than it is now before any mention of the nightingale. The core products seem to be selling. As such it should be worth more now than then. This seems to indicate that the SP is far far to low. Once the Nightingale trial is complete, coupled with core business growth, who knows how far this sp will jump.

I thought the Basingstoke premises was all about Nightingale and Lifebreath products, leaving West Molesey for the distribution of agency products and bespoke AC & air curtain products. A tidy split which in my view might have been organised as a precursor to dividing and possibly selling West Molesey. I am sure the sp will recover but unless they have a strategy and can show a string of steps successfully achieved the sp will just blip up on RNS' and then subside again.
In my view too many have watched and waited for so long that they are now sceptical of some of the current mgt. I am. I do think that they company has great potential and the sp could really fly but I reckon it needs some Board changes before ETQ will regain any credibility; with the exception of the CEO, who one of their smartest chairman always described as the best CEO of a small cap. company he had ever come across.

ETQ is attracting more volume and the sp seems to be firming. They need to do some deals to revitalise this company. Does anyone know anything new that they can share on this thread?

Sharesure,the auditors said results were due today, the company
say 6 weeks, hemscott say update today, results 29th july, take your pick

Doesn't sound too organized! Hope any delay is to include some additional progress as the results are unlikely to be that good in my view. They really need a strategy which will end the drift.

The Protection Agency published results today re hospital infections, makes encouraging readind for those interested in ETQ....

"In July 2004, at the request of the Department of Health (DH), the Health Protection Agency established a rapid review panel to look at future products, materials and techniques that could be used to help prevent the spread of healthcare acquired infections (HCAIs). The review panel has focused its investigations on five key areas that cover all methods of transmission of HCAIs within the hospital environment:

Cleaning, disinfection and decontamination
Fabrics in healthcare
Hand cleansing
Air decontamination

Other technical products including new medical equipment and techniques.
Products reviewed have included disinfectant wipes, wall surface coatings, anti-fungal solutions, nursing uniforms, disposable cubicle curtains, hand-washing systems, sanitisers, AIR PURIFICATION UNITS and catheters."

I don't know of any other company that has their products trialed by the NHS for air purification...

I'll have to check back on details, but there was another company that picked up publicity for air treatment. ETQ infamously decided not to take part in the rapid review panel and did not present its products for consideration. It is not clear if they were doing this because they already had trials going.

What is more important is not what they considered but what outcomes they reached. They could have said air treatment is essential or not cost effective......

do you know the relevant info?


GN

from the HPA website





The review of products by the Rapid Review Panel (the Panel) is undertaken with the specific intent of assessing potential to reduce healthcare associated infections. The views expressed have no intentional bearing on other applications of the product. Information on many products is submitted to the Panel, where the product was specifically designed for, and/or used in, a different setting. Comments from the Panel are not intended for these applications, and should not be interpreted as such.
Further, unless specifically stated, Panel comments do not imply that the product does not meet its primary claims e.g. of sterilising a particular surface or fabric, even if the view of the Panel is that this has no obvious advantage over existing products or will have minimum impact on reducing or preventing healthcare associated infections.


Recommendations:
1.Basic research and development, validation and recent in use evaluations have shown benefits that should be available to NHS bodies to include as appropriate in their cleaning, hygiene or infection control protocols.
2.Basic research and development has been completed and the product may have potential value; in use evaluations/trials are now needed in an NHS clinical setting.
3.A potentially useful new concept but insufficiently validated; more research and development is required before it is ready for evaluation in practice.
4.Unlikely to be of benefit OR not a significant improvement on equipment/materials/products already available which may contribute to reducing health care associated infection; no further consideration needed.
5.Insufficient clarity/evidence presented to enable full review of the product.
6.An already well established product that does not merit further consideration by the Panel.
The product is not sufficiently related to infection control procedures to merit consideration by the Panel.


Air decontamination
There is little evidence to show that air plays a significant role in the transmission of most healthcare-associated infections. In those cases where airborne transmission is thought to be important, both dilution of pathogens in the air and controlling airflow into, or out of, a room are mechanisms for reducing risk. This can be important for protection of highly vulnerable patients (airborne protective isolation) or protection of staff and visitors inside an isolation room, or other patients, staff and visitors outside an isolation room (airborne source isolation). Ventilation systems can be set-up to control directions of airflow and dilution of airborne pathogens. Such dedicated systems can be expensive. There also exist portable systems that recirculate air within a given space. By means of filtration, ultraviolet light or other methods of killing or trapping micro-organisms, they can reduce airborne levels of pathogens but cannot, by these means alone, control airflow into or out of a room. The quality assurance that a system continues to work as intended is vital for any air decontamination regime.
Reports are available for the following products. Please click on a product to view the report.

Air decontamination products Recommendation
Airfree 3

Air Science IQ Portable Air Purification Unit 2

Biozone Scientific products - air sanitiser 5

Fresh Air UV Air Filter 4

GB Environmental Limited Ultra Violet Air Disinfection Unit 4

Growtech Limited Stinger UV Light Emitter 4

Hydroxyl Radical Device 3

Igrox Limited - Medixair 4

It's all about clean air Electromedia model 35F 2

Kostech Ltd Kostech 2K medical filter 3

PhotocatWorks Ltd LightClean antibacterial
coating and air disinfector system 3

Quest International AirManager 6

Steritrox 600 3

Steritrox Plasmalyser 4

Surrey Diagnostics - airocide 3




http://www.hpa.org.uk/infections/topics_az/rapid_review/reports.htm

Global Nomad, good find. Re the Annual Results, think these may be more towards September/October time to allow for a more complete commentary on how the year has gone and where ETQ may be going. Perhaps the Basingstoke Hospital results will be known at that time since that is an important element. I would bet the stumbling block is NHS funding, but if the NHS don't do something they will be sued. I was with a lawyer yesterday who was already handling some hospital infection claims.

Global Nomad, re the argument on whether MRSA is an airborne pathogen or not, I think that that argument is just about won in favour of it being an airborne bug. I think ETQ have always maintained that to be the case but that in conjunction with Nightingale equipment the NHS also need a robust cleaning regime as well.

I didn't doubt the mrsa is in part an airborne pathogen issue, only that theres more than mrsa to deal with.

GN

the rise today was better than of late ( hopefully not reversing monday) maybe a small step up on th elong climb.

GN, Agree MRSA is just one. Probably the bigger prospect is a panic to combat Avian flu. ETQ's technology could be licensed to a volume manufacturer> I would expect their mgt. is on to that but they are a small team, with in my view, a few really key members spread very thinly
As for the sp I am fairly sure that ETQ has the potential to double or treble quite quickly when some positive news gets released. At the moment the price is option money but there must be some doubts in potential investors minds as to how robust the company is so any reluctance to stay with this or jump in is understandable at this stage. I expect that situation to be very different in September, ie after the results (which are likely to be fairly bad) coupled with a decent appraisal of how they go forward. They really need a strategic review and to tell shareholders what that is and then implement it to a firm timetable.

I wonder about this...
http://www.careersinconstruction.com/cic/job/View.do?jobId=207376

If they are advertising for more sales people to join the team then this has got to be good news, at least for the core business.

The recruitment backs up the earlier comments about ETQ winning orders. Lack of news is a problem with ETQ although it seems that they are putting a lot of effort into capitalising on the better trading conditions for their current range of products.

That 500k T trade seems to have been ovrhanging this stock. Maybe now the sp will recover to the 3p-4p band pending announcements. Seems worth a punt at these levels, particularly as there are sufficient large stakes to act as 'insurance' against anything untoward happening. Anyone any other views?